SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trimeris (TRMS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mike head who wrote (28)12/9/1997 9:33:00 PM
From: Elroy Jetson  Read Replies (1) of 108
 
It's understandable that information about business at Trimeris was suddenly hard to come by prior to the IPO.

After the IPO, preliminary information from the T-20 trials showed the drug is extremely effective in controlling HIV (as good as a protease inhibitor), no reported side effects, and no cross-resistance with other drugs due to its unique site of action.

But now, the people associated with Trimeris are boyantly optimistic - almost gleeful, yet will not disclose any information about the company other than the 10-Q filed with the SEC. This is like a second IPO process is ocurring. I'd sure like to be a fly on the wall of CEO Ross Johnson's office.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News